Autopsy report · NCT01331824

Trial of Amrubicin as Second-Line Therapy in Patients With Advanced/Metastatic Refractory Urothelial Carcinoma

“due to a development decision by the funder”

The sponsor’s own words in the registry.

Life of this trial

• Registered 2 months after it had already started.
• Ran for about 4 years 5 months before it stopped.
• 22 participants enrolled.
• Results were posted on the registry 5 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Matthew Galsky

Sponsor type

University, hospital or other

Conditions

Bladder Cancer

Interventions

Amrubicin

Participants

22

Sites

3

Countries

United States

Trials that died the same way

• Prospective Assessment of Patients With Neuroendocrine Tumors and Current or Prior History of Carcinoid Syndrome or Diarrhea Undergoing Peptide Receptor Radionuclide Therapy With or Without Telotristat Ethyl
  “Funder decision” (70% match in meaning)
• High-intensity Focused Ultrasound Study
  “due to funding” (65% match in meaning)
• Study of NIB101 in Participants With Advanced Solid Tumors
  “due to the reconsideration of development strategy” (64% match in meaning)
• Safety and Effectiveness of ABM-168 in Adults with Advanced Solid Tumors.
  “Due to development strategy change.” (62% match in meaning)
• Study to Assess the Safety and Efficacy of an IT Administration of SCM-010 in SPMS
  “Due to sponsor decision” (59% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.